HIms and Hers shares drop after FDA says Lilly's weight-loss drug not in shortage
Shares in telehealth group Hims & Hers Health (NYSE:HIMS) dropped in premarket US trading on Thursday after federal drug regulators said Eli Lilly (NYSE:LLY)'s blockbuster weight-loss and diabetes medications are no longer considered to be in shortage.
The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug ...
The FDA has removed the following items from store shelves this September, including pet food, baby powder and Lactaid.
On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.
The SEC concluded that Cassava Sciences falsified data in its Alzheimer’s clinical trials. Now the FDA needs to act, ...
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...
The U.S. Court of Appeals for the Ninth Circuit on Friday reversed the district court’s judgment in United States v. California Stem Cell ...
The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia, the FDA announced Thursday.
Clarifying the FDA’s Role and Authority Over Direct-to-Consumer Drug Ads ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback